Industry Symposium by Bayer
SY 02 - Primovist enhanced liver MRI – Benefits in HCC liver disease management and patient outcome
Lectures
1
SY02 - Industry Symposium by Bayer: Primovist enhanced liver MRI – Benefits in HCC liver disease management and patient outcome
60:15Bayer.mp4
SY 02-1
30 min
Liver Disease Management & Q/A
Max Seidensticker, Gräfelfing / Germany
Learning Objectives
Present diagnostic results of the SORAMIC trial
Put results into broader context of HCC liver disease management
Significance of results for HCC management in Europe
Trends and data APAC vs. Europe /US
Management of non-enhancing hypointense nodules
Future outlook HCC liver disease management
What would be needed in Europe?
Put results into broader context of HCC liver disease management
Significance of results for HCC management in Europe
Trends and data APAC vs. Europe /US
Management of non-enhancing hypointense nodules
Future outlook HCC liver disease management
What would be needed in Europe?
SY 02-2
30 min
Patient Outcomes & Q/A
Tae Wook Kang, Seoul / Korea, Republic of
Learning Objectives
Present results from nation-wide analysis Korea
Put results into broader context of other HCC outcome studies involving Primovist (+ combination with CT)
Significance of results in APAC
How could learnings from Korea results be transferred to Europe/US?
Future outlook for best practice in HCC management to further lower HCC mortality (in Eastern & Western Countries)
What could Europe/US learn from Korea?
Put results into broader context of other HCC outcome studies involving Primovist (+ combination with CT)
Significance of results in APAC
How could learnings from Korea results be transferred to Europe/US?
Future outlook for best practice in HCC management to further lower HCC mortality (in Eastern & Western Countries)
What could Europe/US learn from Korea?